In this piece we will look at the 5 Best Penny Stocks with Huge Upside Potential. Please visit 10 Best Penny Stocks with Huge Upside Potential if you’d like to see an extended list and how we came up with the list of Best Penny Stocks with Huge Upside Potential.
5. VinFast Auto Ltd. (NASDAQ:VFS)
Number of Hedge Fund Holders: 4
Analyst Upside Potential: 71.92%
VinFast Auto Ltd. (NASDAQ:VFS) is one of the Best Penny Stocks with Huge Upside Potential. On June 1, VinFast Auto Ltd. (NASDAQ:VFS) announced a three-way collaboration with Autobrains and NVIDIA to develop a Level 4 autonomous driving platform specifically for Southeast Asia. The announcement came at NVIDIA GTC Taipei during COMPUTEX 2026.
Management noted that the program runs on NVIDIA DRIVE Hyperion 10 hardware and uses Autobrains’ Agentic AI, which is a system that deploys specialized AI agents only when needed, thereby reducing computing costs and improving real-world performance.
Management also highlighted that Southeast Asia was chosen deliberately as it is dense, and unpredictable traffic makes it one of the toughest environments for autonomous vehicles. These rigorous environments will stress test the autonomous technology. One of the key themes of the platform is affordability. The company noted that many traditional autonomous systems have fallen due to high costs and complexity. This collaboration is set to make Level 4 capability viable without premium pricing.
VinFast Auto Ltd. (NASDAQ:VFS) designs and manufactures electric vehicles. It offers electric scooters (e-scooters) and electric buses (e-buses). It provides an e-mobility ecosystem built around customers, community, and connectivity alongside new vehicle roll-out.
4. Cosan S.A. (NYSE:CSAN)
Number of Hedge Fund Holders: 11
Analyst Upside Potential: 81.47%
On May 26, HSBC downgraded Cosan S.A. (NYSE:CSAN) from Hold to Reduce and also lowered the price target from $5 to $3.2. Overall, analysts’ 12-month price target reflects more than 80% upside from the current level, and the stock is also ranked among our Best Penny Stocks with Huge Upside Potential.
HSBC slashed its price target and outlook mainly due to two core problems, including rising financial expenses, which are impacting the company’s bottom line, and asset sales being executed at unfavorably low prices. The firm noted the restructuring that was carried out in October 2025 to be too little, too late. HSBC notes that Cosan S.A. (NYSE:CSAN) moves have not been enough to offset the damage from a prolonged high-interest-rate environment, which has made its debt burden increasingly costly to manage.
In separate news, the company reported its fiscal Q1 2026 earnings on May 14. Cosan S.A. (NYSE:CSAN) posted a net loss of R$1.6 billion, reflecting a modest R$0.2 billion improvement year-over-year. The result was heavily impacted by R$1.0 billion in costs tied to early repayment of its 2029, 2030, and 2031 bonds. This was seen as a deliberate but expensive move to clean up its debt structure.
On the debt side, expanded net debt rose 18% quarter-over-quarter to R$11.5 billion, driven by the absence of dividend inflows and one-off prepayment costs. However, compared to Q1 2025, net debt decreased 34%, mainly due to a capital raise completed late last year.
Cosan S.A. (NYSE:CSAN) is engaged in the fuel distribution business and in the production of bioethanol, sugar, and energy. The company operates through five segments: Raízen, Compass, Moove, Rumo, and Radar.
3. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Number of Hedge Fund Holders: 33
Analyst Upside Potential: 131.71%
The share price of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has improved more than 11% since the company reported its fiscal Q1 2026 earnings on May 7. Wall Street has also adopted a bullish stance on the stock. For instance, recently on June 1, Citizens reiterated a Market Outperform rating on the stock with a price target of $5. Overall, analysts’ 12-month average price target reflects more than 130% upside. The stock is also ranked among our one of the Best Penny Stocks with Huge Upside Potential.
During the fiscal Q1 2026, Iovance reported total revenue of $71 million, reflecting a 45% increase year-over-year. Management noted that the increase was driven by roughly $60 million in revenue from its flagship cancer therapy Amtagvi and around $11 million from Proleukin. In addition, the gross margins came in at 41%, absorbing some one-time costs from facility maintenance and expansion.
Looking ahead, management has guided for roughly $86 million to $88 million in revenue for the second quarter and roughly $350 million to $370 million for the full year. Iovance also highlighted that Amtagvi’s commercial momentum is building. Management highlighted the real-world response rates of 52% in earlier-stage patients and a median response duration of 3 years in heavily treated patients. Moreover, the treatment network has grown to over 90 authorized centers across the US and Canada, with at least 110 expected by year-end.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor-infiltrating lymphocyte cell therapies for metastatic melanoma and other solid tumor cancers.
2. Nuvation Bio Inc. (NYSE:NUVB)
Number of Hedge Fund Holders: 41
Analyst Upside Potential: 151.05%
Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Penny Stocks with Huge Upside Potential. On May 27, Nuvation Bio Inc. (NYSE:NUVB) presented new patient-reported outcomes from its TRUST-II study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. The presentation was focused on IBTROZI, which treats advanced ROS1-positive non-small cell lung cancer.
The results presented at the meeting were encouraging, with 88% of patients reporting stability at the first assessment, along with improved quality-of-life scores reaching 93% among patients who had previously been treated with other targeted therapies. Management noted that the improvements held steady across multiple time points throughout treatment.
Moreover, the symptom control was also strong, as around 84% to 96% patients reported stable or improved scores for coughing and shortness of breath, with benefits sustained over eight months. Notably, the FDA approved IBTROZI in June 2025 and has since accepted a supplemental application with updated data. Management noted that the final decision is expected by January 2027.
Nuvation Bio Inc. (NYSE:NUVB) is an oncology company focused on developing therapies for cancer treatment.
1. AtaiBeckley Inc. (NASDAQ:ATAI)
Number of Hedge Fund Holders: 35
Analyst Upside Potential: 220.09%
On May 28, AtaiBeckley Inc. (NASDAQ:ATAI), which is a clinical-stage mental health biotech company, announced a Patient Impact Grant Program awarding three grants of $20,000 each to non-profit organizations working to improve mental health outcomes. Analysts expect more than 220% upside over the next 12 months, making AtaiBeckley Inc. (NASDAQ:ATAI) one of the Best Penny Stocks with Huge Upside Potential.
Management noted that the grants cover three focus areas, including community support, education and stigma reduction, and ecosystem innovation and independent research. Under the community support, the grant covers helping organizations expand equitable access to mental health treatments, especially for underserved or historically excluded populations. For the education and stigma reduction theme, the grant is for funding initiatives that promote accurate public understanding of mental health and reduce social stigma. Lastly, for the ecosystem innovation and independent research, the grant is to encourage ethical innovation that strengthens patient access and community trust.
Management noted that the program reflects AtaiBeckley’s broader mission beyond drug development to transform mental health outcomes and bring community-level change.
That said, AtaiBeckley Inc. (NASDAQ:ATAI) reported its fiscal Q1 2026 business update on May 12. Management noted that its lead asset, BPL-003, remains on track to enter Phase 3 trials in Q2 2026. Moreover, two other pipeline assets, including VLS-01 and EMP-01, are also progressing as both assets have shown promising Phase 2 results, with VLS-01 topline data expected by Q4 2026. The company holds $209.9 million in cash, expected to fund operations through 2029.
Atai Beckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders.
While we acknowledge the potential of ATAI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATAI and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 9 Most Undervalued Foreign Stocks to Buy Now and 10 Most Undervalued US Stocks According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
